Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications.
We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.
Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the root cause of the disease rather than just treating the symptoms. Galapagos’ aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.
The Galapagos group, including fee-for-service subsidiairy Fidelta, has approximately 675 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Switzerland, the US and Croatia.